Head and Neck Cancer
Conditions
Keywords
Oncology, KGF, Palifermin, Oral mucositis, Clinical Trial, Amgen, head and neck
Brief summary
The purpose of this study is to evaluate the efficacy and safety of palifermin (recombinant human keratinocyte growth factor, rHuKGF) in reducing the incidence of severe oral mucositis in subjects with locally advanced head and neck cancer receiving radiotherapy with concurrent chemotherapy as adjuvant treatment for their disease.
Detailed description
This study is being conducted to evaluate the efficacy of palifermin administered intravenously (IV) in weekly doses (minimum of 7 weekly doses, until RT was complete) in reducing the incidence of severe (World Health Organization \[WHO\] grade 3 or 4) oral mucositis in subjects with locally advanced HNC receiving RT concurrent with CT (RT/CT) as adjuvant treatment for their disease (postoperative setting). This study will assess the safety and tolerability of palifermin at the dose of 120 μg/kg IV administered weekly (minimum 7 weekly doses, until RT was complete) in this subject population. This study will also evaluate the effect of palifermin on the clinical sequelae of severe OM (eg, average subject-reported mouth and throat soreness \[MTS\] score), and on RT-induced xerostomia in this population, as well as the long-term effects of palifermin on disease outcome and survival in this population.
Interventions
DRUGPlacebo
Single IV dose of placebo at 120 μg/kg, 3 days before the start of Radiotherapy, plus 6 once weekly placebo doses at the same dose during a 6-week radiotherapy / chemotherapy course.
DRUGPalifermin
Single IV dose of palifermin at 120 μg/kg, 3 days before the start of radiotherapy plus 6 once weekly palifermin doses at the same dose level during a 6-week Radiotherapy / chemotherapy course
Sponsors
Amgen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* History of histologically documented squamous cell carcinoma ( AJCC \[American Joint Committee on Cancer\] Stage II, III, IVA or IVB) involving either the oral cavity, oropharynx, hypopharynx, or larynx,post surgical resection (R0, R1) and candidates for adjuvant RT/CT * Radiation treatment field to receive planned dose of at least 50Gy to area of the oral cavity/oropharynx mucosa that can be visualized * Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2 * Functional hematopoietic and hepato-renal systems
Exclusion criteria
* Tumors of the lips, paranasal sinuses, salivary glands, or unknown primary tumors * Metastatic disease (M1) Stage IV C * Presence or history of any other primary malignancy (other than curatively treated in situ cervical cancer or basal cell carcinoma of the skin) * History of chronic pancreatitis or episode of acute pancreatitis within the last year * Prior radiation to the site of the disease, or prior chemotherapy-
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence percentage of severe oral mucositis (Grades 3 or 4 on the WHO oral mucositis scale) | Up to 24 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Time to onset of severe oral mucositis (WHO Grades 3 or 4) | 12 weeks |
| Total dose of opioid analgesics used (mg of morphine equivalents) | 16 weeks |
| Incidence of unplanned delays in CT for cisplatin administration on Day 22 (to include discontinuations of CT) | 12 weeks |
| Average patient-reported mouth and throat soreness score (as reported on Question 3 of the Oral Mucositis Weekly Questionnaire for patients with Head and Neck cancer [OMWQ-HN] | 16 weeks |
| Duration of severe oral mucositis (WHO Grades 3 or 4) | 15 weeks |
| Incidence of >/equal to 5 missed consecutive fractions of scheduled RT (to include discontinuations of RT) | 12 weeks |
| Incidence of xerostomia (CTCAE v3.0 Dry Mouth/Xerostomia scale Grade 2 or higher) | 10 years |
Outcome results
None listed